Cogent Biosciences (COGT) Cash from Operations (2017 - 2021)
Historic Cash from Operations for Cogent Biosciences (COGT) over the last 5 years, with Q4 2021 value amounting to -$20.8 million.
- Cogent Biosciences' Cash from Operations fell 12183.43% to -$20.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$58.8 million, marking a year-over-year decrease of 6391.35%. This contributed to the annual value of -$207.8 million for FY2024, which is 3525.95% down from last year.
- Per Cogent Biosciences' latest filing, its Cash from Operations stood at -$20.8 million for Q4 2021, which was down 12183.43% from -$14.1 million recorded in Q3 2021.
- Cogent Biosciences' Cash from Operations' 5-year high stood at -$5.8 million during Q2 2017, with a 5-year trough of -$20.8 million in Q4 2021.
- For the 5-year period, Cogent Biosciences' Cash from Operations averaged around -$9.7 million, with its median value being -$8.7 million (2018).
- As far as peak fluctuations go, Cogent Biosciences' Cash from Operations skyrocketed by 3147.25% in 2020, and later crashed by 12183.43% in 2021.
- Quarter analysis of 5 years shows Cogent Biosciences' Cash from Operations stood at -$6.5 million in 2017, then crashed by 38.43% to -$9.0 million in 2018, then grew by 6.37% to -$8.4 million in 2019, then fell by 10.91% to -$9.4 million in 2020, then tumbled by 121.83% to -$20.8 million in 2021.
- Its Cash from Operations was -$20.8 million in Q4 2021, compared to -$14.1 million in Q3 2021 and -$12.5 million in Q2 2021.